Clinical Implications of Acquired BRAF Inhibitors Resistance in Melanoma
Understanding the role of mitogen-activated protein kinase (MAPK) pathway-activating mutations in the development and progression of melanoma and their possible use as therapeutic targets has substantially changed the management of this neoplasm, which, until a few years ago, was burdened by severe...
Main Authors: | Paola Savoia, Elisa Zavattaro, Ottavio Cremona |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-12-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/21/24/9730 |
Similar Items
-
Triple Combination of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in <i>BRAF</i>V600 Melanoma: Current Status and Future Perspectives
by: Michèle Welti, et al.
Published: (2022-11-01) -
NAMPT Over-Expression Recapitulates the BRAF Inhibitor Resistant Phenotype Plasticity in Melanoma
by: Valentina Audrito, et al.
Published: (2020-12-01) -
Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review
by: Ilaria Proietti, et al.
Published: (2020-09-01) -
Case Report: Rechallenge With BRAF and MEK Inhibitors in Metastatic Melanoma: A Further Therapeutic Option in Salvage Setting?
by: Anna Stagno, et al.
Published: (2021-05-01) -
Case Report: Dynamic overlap of melanoma, sarcoidosis, and targeted therapy for BRAF-mutant melanoma
by: Nakul Dar, et al.
Published: (2023-08-01)